| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Enzalutamide |
| Brand | Xtandi® |
| Indication | First line treatment of adult men with mCRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated |
| Assessment Process | |
| Rapid review commissioned | 05/11/2014 |
| Rapid review completed | 22/12/2014 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full pharmacoeconomic assessment commissioned by HSE | 09/04/2015 |
| NCPE assessment completed | 22/06/2015 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
December 2015
The HSE has approved reimbursement following confidential price negotiations.
